Scarica l'app Stockscreener
27.66
1.92%
0.52
Dopo l'orario di chiusura:
27.66
Agios Pharmaceuticals Inc Borsa (AGIO) Ultime notizie
BofA Adjusts Price Target on Agios Pharmaceuticals to $52 From $54, Keeps Buy Rating - MarketScreener
Agios Pharmaceuticals (AGIO) Price Target Lowered by BofA but Buy Rating Maintained | AGIO Stock News - GuruFocus
Agios to Webcast Conference Call of First Quarter Financial Results on May 1, 2025 | AGIO Stock News - GuruFocus
Agios Pharmaceuticals to Host Conference Call for Q1 2025 Financial Results on May 1, 2025 - Nasdaq
Agios to Webcast Conference Call of First Quarter Financial Results on May 1, 2025 - TradingView
Trexquant Investment LP Increases Holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - MarketBeat
Agios Pharmaceuticals director Jacqualyn Fouse sells $194,172 in stock By Investing.com - Investing.com South Africa
Agios Pharmaceuticals Director Sells Shares to Cover Tax Obligations - TradingView
Agios Pharmaceuticals director Jacqualyn Fouse sells $194,172 in stock - Investing.com
Agios stock touches 52-week low at $24.33 amid market challenges - Investing.com Australia
Agios stock touches 52-week low at $24.33 amid market challenges By Investing.com - Investing.com South Africa
Small to Mid-Cap Biotechnology Firms Likely to Continue to Face Macro Headwinds, BofA Securities Says - MarketScreener
Agios stock touches 52-week low at $27.12 amid market shifts - Investing.com India
Agios stock touches 52-week low at $27.12 amid market shifts By Investing.com - Investing.com South Africa
Is Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) the Best Small Cap Stock to Buy Before They Explode? - Insider Monkey
Agios Pharmaceuticals develops PAH mutant stabilizers for phenylketonuria - BioWorld MedTech
First Week of November 21st Options Trading For Agios Pharmaceuticals (AGIO) - Nasdaq
Agios Pharmaceuticals divulges new PAH stabilizers for phenylketonuria - BioWorld MedTech
Beta Thalassemia Market Predicted to See Upsurge Through 2034, - openPR
Agios Pharmaceuticals at Barclays Conference: Strategic Advances in Rare Disease Treatments - Investing.com UK
Agios Pharm at Leerink’s Global Healthcare Conference: Strategic Insights By Investing.com - Investing.com Canada
Q1 EPS Estimate for Agios Pharmaceuticals Lowered by Analyst - Defense World
FY2027 Earnings Estimate for AGIO Issued By Zacks Research - Defense World
Agios Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Corporate Development & Strategy Officer - The Manila Times
Agios Pharmaceuticals Announces Inducement Equity Awards for New Executive - GuruFocus.com
Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Corporate - EIN News
Celldex Therapeutics and Agios Pharmaceuticals to Present at March 2025 Investor Conferences - Barchart
Meet Agios' New Strategy Chief: Inside the $2M+ Executive Compensation Deal - Stock Titan
Agios Pharmaceuticals chief commercial officer sells $59,742 in stock By Investing.com - Investing.com South Africa
Agios Pharmaceuticals chief commercial officer sells $59,742 in stock - Investing.com India
Agios Pharmaceuticals CEO sells shares worth $460,135 - Investing.com
Agios to Present at Upcoming Investor Conferences - The Manila Times
Where to Hear Agios Management Next Month: Key Investor Conferences Revealed - StockTitan
Insmed, Agios rise; DraftKings, Atlantica fall, Tuesday, 5/28/2024 - Star Tribune
Is Agios Pharmaceuticals, Inc. (AGIO) the Best Small-Cap Stock to Buy Now? - Insider Monkey
Y Intercept Hong Kong Ltd Acquires Shares of 45,817 Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - MarketBeat
What is HC Wainwright's Estimate for AGIO Q1 Earnings? - MarketBeat
Earnings call transcript: Agios Pharm Q4 2024 beats EPS forecast, stock rises - MSN
10 Best Small-Cap Stocks to Buy Now - Insider Monkey
Gilbert Cisneros conducts multiple transactions in stocks including Agios Pharmaceuticals and Airbnb - MSN
Sickle Cell Disease Market Growth Projections 2024-2034: - openPR
Q4 Earnings Estimate for AGIO Issued By HC Wainwright - MarketBeat
Venturi Wealth Management LLC Takes Position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - Defense World
What is HC Wainwright’s Estimate for AGIO Q4 Earnings? - Defense World
Agios Bolsters Coffers With $1.1 Bln Milestone Payments Following FDA Approval Of Vorasidenib - RTTNews
H.C. Wainwright sets $58 target on Agios Pharma stock with Buy rating By Investing.com - Investing.com South Africa
H.C. Wainwright starts Agios Pharmaceuticals coverage with 'buy' - TradingView
H.C. Wainwright sets $58 target on Agios Pharma stock with Buy rating - Investing.com India
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Short Interest Down 6.0% in January - MarketBeat
Agios to Present at the TD Cowen 45th Annual Healthcare Conference on March 3, 2025 - The Manila Times
Why Agios Pharmaceuticals' (NASDAQ:AGIO) Earnings Are Weaker Than They Seem - Simply Wall St
Rare Disease Leader Agios Takes Center Stage at Major Healthcare ConferenceKey Details Inside - StockTitan
2.51%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):